Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

A small but rigorous randomized trial suggests paracetamol may be a feasible alternative to ibuprofen for late PDA treatment, while underscoring the need for larger multicenter studies to guide ...

“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

A groundbreaking advancement in paediatric heart care is transforming how doctors treat one of the most common and ...

The Bedside Cardiac Procedure, Once Requiring Transport of Fragile NICU patients to a Catheterization Lab, is now performed directly in the NICU by Nicklaus Children's Hospital Heart Institute Doctors ...

Philadelphia, PA - Using a strategy that takes the classic "house-call" to new extremes, a traveling medical team made up of cardiothoracic surgeons, anesthesiologists, and nurses is bringing a ...

Objective: To provide commentary and reviews and brief discussions in controversial or innovative recent advances in neonatal pharmacotherapy. To discuss cutting edge drug delivery systems that may ...